Current Report Filing (8-k)
April 12 2017 - 9:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
____________________________________________________________
Date of Report (Date of earliest event reported):
April 12, 2017
RASNA THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in
Charter)
Nevada
|
|
333- 191083
|
|
39-2080103
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
420 Lexington Avenue, Suite 2525,
New York, NY
|
|
10170
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: 646-396-4087
(Former name or former address, if changed
since last report)
Copies to:
Jeffrey Fessler, Esq.
Sheppard, Mullin, Richter & Hampton
LLP
30 Rockefeller Plaza
New York, New York 10112
Telephone: (212) 653-8700
Facsimile: (212) 653-8701
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On April 12, 2017, Rasna Therapeutics,
Inc. issued a press release announcing that it has qualified and is now trading on the OTCQX® Best Market, operated by OTC
Markets Group).
The press release is attached as Exhibit 99.1
to this report on Form 8-K and is incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
|
99.1
|
Rasna Therapeutics, Inc. Press Release dated April 12,
2017.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: April 12, 2017
|
RASNA THERAPEUTICS, INC.
|
|
|
|
|
|
|
By:
|
/s/
Tiziano Lazzaretti
|
|
|
|
Name: Tiziano Lazzaretti
|
|
|
|
Title: Chief Financial Officer
|
|
Actavia Life Sciences (PK) (USOTC:RASP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actavia Life Sciences (PK) (USOTC:RASP)
Historical Stock Chart
From Apr 2023 to Apr 2024